2018 highlights January Acquire Advanced Accelerator Applications (AAA) The acquisition strengthens our oncology portfolio Obtain ex-US rights to breakthrough gene therapy Luxturna, from Spark Therapeutics, treats rare vision loss Announce FDA approval of Lutathera Developed by AAA, the drug is approved to treat certain neuroendocrine tumors February Launch Glatopa 40 mg/mL in the US It is a generic option for relapsing forms of MS March Develop digital therapeutics We are working with Pear Therapeutics on treatments for schizophrenia and MS; Pear Therapeutics and Sandoz launched a substance use disorder app in November Expand alliance with Science 37 The agreement aims to advance virtual clinical trials Receive FDA approval for Tasigna in new indication Tasigna is approved to treat children with a rare form of leukemia April Renew commitment to malaria elimination USD 100 million to go toward R&D over the next five years Launch app to modernize ophthalmic clinical trials With FocalView, patients can participate in trials from home Obtain FDA approval for Tafinlar + Mekinist in new indication Approval is for the adjuvant treatment of BRAF V600-mutant melanoma May Receive FDA approval for Kymriah in second indication It is approved to treat appropriate r/r patients with large B-cell lymphoma Secure FDA approval for Gilenya in new indication It is the first disease-modifying therapy for pediatric relapsing MS Complete AveXis acquisition The deal could help transform spinal muscular atrophy treatment Announce FDA approval of Aimovig The novel drug was developed with Amgen specifically for migraine prevention Receive EU approval for biosimilar Zessly It treats gastroenterological, rheumatological and dermatological diseases June Complete sale of stake in consumer healthcare business The GSK joint venture was formed during our portfolio transformation Announce planned Alcon spin-off We will seek shareholder approval at the 2019 AGM July Announce expanded indications for Kisqali in the US It is approved to treat pre-, peri- or postmenopausal women with HR+/HER2- advanced or metastatic breast cancer Receive EU approval for biosimilar Hyrimoz It is the seventh Sandoz biosimilar approved in Europe Obtain EU approval for Aimovig It is the first drug of its kind approved in the EU, the US, Switzerland and Australia August Announce EU approval of Kymriah Approval is for two forms of blood cancer Secure third European approval for Tafinlar + Mekinist It is for the adjuvant treatment of advanced melanoma September Announce plans to sell portions of the Sandoz US portfolio We will divest the US dermatology and generic oral solids businesses to Aurobindo October Receive FDA and EMA filing acceptance for BAF312 (siponimod) If approved, the drug would treat secondary progressive MS in adults November Rise to second place in the 2018 Access to Medicine Index We remain the industry leader in one area: access-to-medicine management Receive EU approval for Luxturna It is the first gene therapy to treat an inherited retinal disease December Complete Endocyte acquisition Endocyte is focused on developing radioligand and CAR-T therapies for cancer treatment
